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Abstract
Background: This study aimed to determine the prevalence of polycystic ovary syndrome (PCOS) in Iranian women based on different 
diagnostic criteria. 
Material and methods: This cross-sectional study was conducted in 2009 in Isfahan, Iran among females referred to the mandatory 
pre-marriage screening clinic. Menstrual irregularity was assessed as the presence of chronic amenorrhea or a menstrual cycle length of 
less than 21 days or more than 35 days, or more than four days of variation between cycles. Clinical hyperandrogenism was assessed as 
the self-reported degree of hirsutism using the modified Ferriman Gallwey (mF-G) scoring method based on a chart displaying degree of 
hair growth in nine regions. Those participants who reported menstrual irregularity and/or who had an mF-G score of ≥ 8 were invited for 
a clinical examination. Those who did not have these criteria were not further evaluated and were deemed not to have PCOS. Participants 
with abnormal findings underwent blood test and abdominal sonography of their ovaries. In those with hirsutism, serum was obtained on 
the 22nd–24th day of the cycle for the measurement of progesterone; free testosterone was measured in those with menstrual irregularity. 
Results: The estimated prevalence of PCOS was 7% based on the NIH criteria, 15.2% under the Rotterdam criteria, and 7.92% according 
to the AES criteria.
Conclusion: The Rotterdam prevalence estimates were double those obtained with the NIH criteria. This study can be used for interna-
tional comparisons because it was conducted on a representative sample of females using different criteria for the definition of PCOS. 
(Pol J Endocrinol 2011; 62 (3): 238–242)
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Introduction
Polycystic ovary syndrome (PCOS) is the commonest 
endocrine disorder in women of reproductive age [1]. 
These patients are at higher risk of developing infertility, 
dysfunctional uterine bleeding and a number of meta-
bolic disorders including insulin resistance, diabetes 
mellitus, hypertension and dyslipidemia [2]. 
In spite of the potential public health impact of 
PCOS, estimates regarding its prevalence are surpris-
ingly scarce, with wide variations ranging from 2.2% 
to as high as 26% [3]. This variability could be due to 
several factors, one of the most important being the 
difference in diagnostic criteria used. Currently there 
are three definitions of PCOS usually used. 
The first arose from the proceedings of an expert 
conference sponsored in part by the National Institute 
of Child Health and Human Disease of the U.S. National 
Institute of Health (NIH) in 1990.The NIH diagnostic cri-
teria state that women have PCOS if they present with 
the combination of chronic oligo- and/or anovulation 
and clinical or biochemical signs of hyperandrogenism, 
with the exclusion of related disorders [4].
The second expert conference was convened in 
Rotterdam, the Netherlands in 2003 by the European 
Society for Human Reproduction and Embryology and 
the American Society for Reproduction Medicine. The 
meeting recommended that PCOS be defined when at 
least two of the following three features were present: 
— oligo- and/or anovulation
— hyperandrogenism
— polycystic ovaries. 
These criteria also recognise that other causes of an-
drogen excess and related disorders should be excluded 
before confirming the diagnosis of PCOS [5–6].
The third and the most recent set of criteria was 
defined by a task force of the Androgen Excess Society 
(AES) in 2006, which recommended the following di-
agnostic criteria for PCOS:
— hirsutism and/or hyperandrogenism;
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— oligo- and anovulation and/or polycystic ovaries;
— other androgen excess or related disorders should 
be excluded [7].
Another suggestion for the marked differences in the 
prevalence of PCOS is that the clinical characteristics 
and biochemical features of these patients may vary 
according to race and ethnicity [8]. Furthermore, the 
prevalence of PCOS may differ according to the age and 
the population studied. The prevalence of PCOS seems 
to be higher in younger women than in those aged over 
35 years [9]. Moreover, differing populations in various 
studies affect the estimated prevalence of PCOS.
For instance, the study by Azziz et al. among 400 
non-randomly selected pre-menopausal women, aged 
18–45 years, seeking a pre-employment physical at the 
University of Alabama found a PCOS prevalence of 8% 
in black and 4.8% in white women based on the NIH 
criteria [10]. The study by Asuncion et al. conducted 
among 154 white female blood donors Spain found 6.5% 
to have PCOS based on NIH criteria [11]. Compared to 
the general population, university employees are likely 
to have higher socio-economic status, and blood donors 
are likely to be healthier. Thus such information cannot 
be representative and should not be generalised.
Information about the prevalence of PCOS in the 
Iranian population is scarce. The aim of this study was 
to estimate the prevalence of PCOS in a representative 
sample of Iranian females, and to compare it according 
to different sets of criteria.
Material and methods
This cross-sectional study was conducted in 2009 in 
Isfahan, the second largest city in Iran. The study 
population comprised females referred to the manda-
tory pre-marriage screening clinic affiliated to Isfahan 
University of Medical Sciences. These females were 
invited to participate in PCOS screening. This study 
was approved by the Ethics Committee of Isfahan Uni-
versity of Medical Sciences. Written informed consent 
was obtained from all participants.
A resident of Obstetrics and Gynaecology conducted 
interviews by taking a medical history and focusing 
on symptoms of PCOS, specifically menstrual irregu-
larities, clinical hyperandrogenism and medication 
use including hormone therapy. Weight and height 
were measured by standard protocol and calibrated 
instruments. Body mass index (BMI) was calculated as 
weight (kg) divided by height squared (m2). Menstrual 
irregularity was assessed as the presence of chronic 
amenorrhea or a menstrual cycle length of less than 
21 days or more than 35 days, or more than four days 
variation between cycles. Clinical hyperandrogenism 
was assessed as the self-reported degree of hirsutism 
using the modified Ferriman Gallwey (mF-G) scoring 
method based on a chart displaying degree of hair 
growth in nine regions. 
Those participants who reported menstrual irregu-
larity and/or had an mF-G score of 8 were invited for 
a clinical examination. Those who did not have these 
criteria were not further evaluated and were deemed 
not to have PCOS. 
All participants with abnormal findings consented to 
a blood test and an abdominal sonography of their ova-
ries; vaginal sonography was not considered because 
they were virgins. Serum TSH (TSH.IRMA Pooyesh 
Tashkhis, Tehran, Iran), prolactin (PRL, IRMA Pooyesh 
Tashkhis, Tehran, Iran) and 17-hydroxyprogesterone 
levels were measured. In addition, in participants with 
only hirsutism, serum was obtained on the 22nd–24th day 
of the menstrual cycle for the measurement of proges-
terone to confirm ovulatory function. A progesterone 
level of less than 4 ng/ml indicated anovulation for 
evaluation purposes. In women with only menstrual 
irregularity, free testosterone was measured. Free tes-
tosterone was used to assess hyperandrogenemia 
because it was considered one of the more sensitive 
methods in the Rotterdam ESHRE/ASRM-sponsored 
PCOS consensus workshop group [5]. Free testosterone 
was calculated from the total testosterone and SHBG 
levels. A testosterone level higher than 0.75 ng/dl con-
sidered to be high. Clinical hirsutism was defined by 
an mF-G score ≥ 8 derived from the 95th percentile of 
this population of healthy non-hirsute eumenorrheic 
women. Ultrasonography (US) was performed for par-
ticipants with menstrual dysfunction and/or hirsutism. 
Polycystic ovaries were identified on ultrasonogra-
phy (ALOKA 1000, 7.5 MHz probe) by either 12 or more 
follicles with a 2–9 mm diameter, or increased ovarian 
volume ( > 10 cm) in at least one of the ovaries [11, 12].
Then, participants were subdivided according to 
the presence or absence of menstrual dysfunction or 
anovulation, hirsutism or high free testosterone (HA) 
and polycystic ovary on US into four groups:
— menstrual dysfunction and hirsutism or hyperan-
drogenemia;
— menstrual dysfunction and PCO morphology in US;
— hirsutism or hyperandrogenemia and PCO mor-
phology in US;
— menstrual dysfunction and hyperandrogenemia or 
hirsutism and PCO morphology in US.
Confirmed PCO was established in those individuals 
whose evaluation was complete and met the abovemen-
tioned criteria. Possible PCOS was considered when the 
evaluation was not complete or was unavailable, but 
the clinical phenotype was suggestive of this disorder. 
The individual probability of PCOS in women with 
possible PCOS was assigned a weight based on the find-
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ings in similar subjects whose evaluation was complete, 
i.e. number of confirmed PCOS in category/number of 
patients with complete evaluation. The number of ad-
ditional calculated PCOS was considered as equal to the 
number of women with possible PCOS probability that 
patients with possible PCOS have PCOS.
Data analysis was performed using SPSS version 
15.0 (SPSS Inc., Chicago, USA). 
Results
Between May 1–28, 2009, a total of 1,182 females, aged 
17–34, attended the aforementioned pre-marriage clinic. 
They were invited to participate in PCOS screening. Two 
subjects were excluded due to thyroid hormone replace-
ment therapy, and 360 (30.5%) refused to participate, 
giving a total of 820 subjects (69.5% of invited individu-
als) available for the current study. Those individuals 
who refused to participate in this study did not differ 
from the participants in terms of mean age (24.2 ± 5.3 
vs. 24.8 ± 5.1 years, respectively), or BMI (25 ± 6.7 
vs. 25.7 ± 4.3 kg/m2, respectively) (Table I).
Overall, 19% of participants were overweight (BMI: 
25.0–29.9 kg/m2) and 9% were obese (BMI 30 kg/m2). 
Hormone therapy for treatment of menstrual dysfunc-
tion or hirsutism was documented in 15 individuals; as 
the prevalence of hirsutism and menstrual dysfunction 
before hormone therapy did not differ from those not 
under treatment, they were not excluded from the study. 
For determination of PCOS, participants were subdivided 
based on the presence or absence of menstrual dysfunc-
tion and hirsutism into four groups (Figure 1): 
1. Individuals without menstrual dysfunction and 
hirsutism: of the 820 participants, 599 were eumen-
orrheic and non-hirsute, therefore the diagnosis of 
PCOS was ruled out.
2. Individuals with menstrual dysfunction only: 175 
subjects (21.3% of the total) had menstrual dys-
function without hirsutism. Of these 175 subjects, 
six (3.42%) had amenorrhea, 16 (9.10%) and 99 
(56.5%) had menstrual cycle length of less than 21 
days and more than 35 days respectively, and 54 
(30.8%) had more than four days’ variation between 
cycles. Overall, 91 subjects had complete evaluation 
by US and blood tests (Figure 1). The remaining 
77 subjects had incomplete evaluations, and were 
considered to have possible high testosterone or 
PCO morphology in US. The individual’s probabil-
ity of  high testosterone or PCO morphology was 
calculated within each phenotype by multiplying 
the proportion with high testosterone or PCO mor-
phology in the group completing evaluation, by 
the number not undertaking an evaluation (e.g. for 
calculation of probability of high testosterone and 
PCO morphology 4/91  77 (91 subjects completed 
evaluation of whom  four had high testosterone 
and PCO morphology, and 77subjects in this group 
had incomplete evaluation). 
3. Individuals with hirsutism only: 33 subjects had 
hirsutism without menstrual dysfunction, 22 had 
complete evaluation (Figure 1). 
4. Individuals with menstrual dysfunction and 
hirsutism: 25 subjects had hirsutism + MD. The 
cumulative number of PCOS subjects in the study 
population included 57.77 subjects among 820 wo-
men in the group with the NIH criteria, and 124.67 
subjects among 820 women in the group with the 
Rotterdam criteria, and 67.70 subjects among 820 in 
the AES group. The prevalence of PCOS according 
to the NIH, AES and Rotterdam criteria was 7, 7.92 
and 12.50 per cent respectively. 
Discussion 
In spite of the considerable reproductive, endocrine 
and metabolic morbidity of PCOS, little is known of its 
prevalence in the general population. Because of differ-
ences in terms of ethnicity and the clinical characteristics 
Table I. Mean (SD) of characteristics and F-G grade for hirsutism in four groups of patients with polycystic ovary syndrome 
HA+ MD HA + PCO MD + PCO MD + HA + PCO
Age (years) 29.11 ± 3.59 38.31 ± 2.9 28.98 ± 8.9 28.89
Height [cm] 160 ± 5.4 161 ± 4.4 160 ± 65 160 ± 9.1
Weight [kg] 67 ± 17.9 63 ± 9.2 65 ± 12.1 64 ± 13.1
Body mass index [kg/m2] 25.7 ± 4.3 25.3 ± 5.6 25.12 ± 4.6 25 ± 6.7
Waist circumference [cm] 80.7 ± 11 80 ± 13 78 ± 9.9 79 ± 15
Hip circumference [cm] 102.5 ± 8 101.6 ± 11 99 ± 8.4 101 ± 13
F-G grade 7.8 ± 6.5 7.9 ± 2.9 3.92 ± 1.92 7.8 ± 4.5
PCO — polycystic ovary syndrome; HA — hirsutism; MD — menstrual dysfunction
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and biochemical features, Iranian PCOS patients may 
differ from those of other populations [8]. 
In the current study, participants were of similar 
ethnic origin and included a population who were man-
dated to attend the pre-marriage clinic. In our study, the 
prevalence of PCOS was 7% based on NIH criteria. The 
corresponding figures were 6.5% in the study by Asun-
cion et al., conducted among 154 Caucasian women of 
reproductive age referred for blood donation [11], and 
6.6% in the study by Azziz et al., performed among 
400 non-random samples of pre-menopausal women 
seeking pre-employment physical examination [10]. 
The higher prevalence obtained in our study may be 
because of the larger number and the community-based 
nature of the participants included in our study. These 
are the main strengths of our study. 
The prevalence of PCOS in our study was 15.2% 
based on Rotterdam criteria, i.e. more than twice the 
prevalence obtained based on NIH criteria. This preva-
lence was 12% in the study by Lowe et al., conducted 
among 100 subjects non-randomly selected from female 
partners of azospermic men [13], and 17.8% in the 
study by March et al. performed among 728 women 
[14]. Taking into account that the prevalence of PCOS is 
reported to be somewhat higher by using trans-vaginal 
US [9, 15], the lower prevalence of PCOS, based on Rot-
terdam criteria, in our study compared to the study by 
March et al. might be because they used  trans-vaginal 
US, whereas we used  trans-abdominal US. 
By considering the AES criteria, the prevalence of 
PCOS was 7.92 % in our study, and was lower than the 
prevalence of 12% documented in the study by March 
et al. [14]. This difference might be because of ethnic 
differences and variations in androgen assay.
Given that a healthy lifestyle, notably exercise train-
ing, is documented to have beneficial effects on the car-
diopulmonary system in PCOS women [16], screening 
and early detection of this syndrome would be helpful 
in advising lifestyle change, and in turn reducing the 
risk of cardiovascular diseases.
Conclusion
The concept that many cases of PCOS can be diagnosed 
based on the Rotterdam criteria, but not based on the 
NIH and AES criteria, should be considered in new sets 
of diagnostic criteria for PCOS in the community. The 
representative sample of participants studied, and the 
use of different criteria for the definition of PCOS in 
the current study, provide useful data for international 
comparisons. 
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